Brii Biosciences Limited (HKG:2137)

Market Cap	1.46B
Revenue (ttm)	134.48M
Net Income (ttm)	-411.68M
Shares Out	719.38M
EPS (ttm)	-0.56
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,555,000
Average Volume	9,504,733
Open	2.060
Previous Close	2.040
Day's Range	2.010 - 2.100
52-Week Range	0.800 - 3.090
Beta	1.42
RSI	50.10
Earnings Date	Aug 19, 2025

About Brii Biosciences

Brii Biosciences Limited focuses on developing therapies for the treatment of infectious and central nervous system diseases in China and the United States. The company develops BRII-179, a recombinant protein-based HBV immunotherapeutic candidate; Elebsiran, an investigational subcutaneously administered HBV-targeting siRNA; and Tobevibart, an investigational subcutaneously administered HBV-neutralizing monoclonal antibody which are in Phase 2 of the development stage for functional cure of HBV for Hepatitis B; and BRII-732 that has completed ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Employees: 98
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2137

Financial Performance

In 2024, Brii Biosciences's revenue was 49.94 million, a decrease of -10.65% compared to the previous year's 55.89 million. Losses were -508.16 million, 190.7% more than in 2023.

Financial numbers in CNY